| Gastrointestinal Stromal Tumors
Stivarga vs Sutent
Side-by-side clinical, coverage, and cost comparison for gastrointestinal stromal tumors.Deep comparison between: Stivarga vs Sutent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSutent has a higher rate of injection site reactions vs Stivarga based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sutent but not Stivarga, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Stivarga
Sutent
At A Glance
Oral
Once daily (21 of 28 days)
Multikinase inhibitor
Oral
Daily
Multi-targeted RTK inhibitor
Indications
- Metastasis from malignant neoplasm of colon and/or rectum
- Gastrointestinal Stromal Tumors
- Liver carcinoma
- Gastrointestinal Stromal Tumors
- Renal Cell Carcinoma
- Well Differentiated Pancreatic Endocrine Neoplasm
Dosing
Metastasis from malignant neoplasm of colon and/or rectum, Gastrointestinal Stromal Tumors, Liver carcinoma 160 mg orally once daily for the first 21 days of each 28-day cycle, taken after a low-fat meal; continue until disease progression or unacceptable toxicity.
Gastrointestinal Stromal Tumors, Renal Cell Carcinoma 50 mg orally once daily on Schedule 4/2 (4 weeks on, 2 weeks off); adjuvant RCC limited to a maximum of nine 6-week cycles.
Well Differentiated Pancreatic Endocrine Neoplasm 37.5 mg orally once daily until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) pain, HFSR/PPES, asthenia/fatigue, diarrhea, decreased appetite/food intake, hypertension, infection, dysphonia, hyperbilirubinemia, fever, mucositis, weight loss, rash, nausea
Serious hepatotoxicity, infections, hemorrhage, gastrointestinal perforation or fistula, dermatological toxicity, hypertension, cardiac ischemia and infarction, reversible posterior leukoencephalopathy syndrome
Postmarketing hypersensitivity reaction, nephrotic syndrome, cardiac failure, arterial aneurysms/dissections/rupture
Most common (>=25%) Fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, thrombocytopenia.
Serious Hepatotoxicity, cardiovascular events, QT interval prolongation and Torsade de Pointes, hemorrhagic events, tumor lysis syndrome, thrombotic microangiopathy, proteinuria, dermatologic toxicities, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, hypoglycemia, osteonecrosis of the jaw, impaired wound healing.
Postmarketing Hemorrhage associated with thrombocytopenia, esophagitis, acalculous cholecystitis, hypersensitivity reactions including angioedema, serious infection, fistula formation, myopathy/rhabdomyolysis, renal impairment/failure, pulmonary embolism, pleural effusion, pyoderma gangrenosum, arterial aneurysms/dissections/rupture, arterial thromboembolic events.
Pharmacology
Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in oncogenesis, tumor angiogenesis, metastasis, and tumor immunity, including VEGFR1-3, KIT, PDGFR-alpha/beta, FGFR1/2, RAF-1, BRAF, and CSF1R.
Sunitinib is a small-molecule inhibitor of multiple receptor tyrosine kinases (RTKs) including PDGFRalpha/beta, VEGFR1/2/3, KIT, FLT3, CSF-1R, and RET, which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Stivarga
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Sutent
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Stivarga
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Sutent
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Stivarga
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Sutent
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Stivarga.
$0/fillfill
Sutent Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
StivargaView full Stivarga profile
SutentView full Sutent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.